Last updated: February 23, 2026
What is NDC 60505-0102?
NDC 60505-0102 identifies a drug marketed by Teva Pharmaceuticals. It is a generic version of a branded medication, with indications, pharmacology, and market positioning aligned with similar therapeutic agents. The precise formulation and strength are critical to understanding market dynamics and pricing.
Market Overview
Therapeutic Class
The drug falls within the [Therapeutic Class], targeting [Indication or Disease Area]. It competes with other generics and branded drugs in the same therapeutic segment.
Competition Landscape
| Drug Name |
Manufacturer |
Strength/Formulation |
Approval Date |
Market Share (%) (2022) |
| Brand Name (if applicable) |
[Brand] |
[Strength/Package] |
[Date] |
[Data] |
| Generic Version (NDC) |
Teva |
[Strength/Package] |
[Date] |
[Data] |
| Competitor A |
[Company] |
[Strength/Package] |
[Date] |
[Data] |
| Competitor B |
[Company] |
[Strength/Package] |
[Date] |
[Data] |
Market Size and Growth Trends
- The U.S. prescription volume for this class was approximately X million units in 2022.
- The compound annual growth rate (CAGR) from 2018-2022 stood at Y%.
- The emergence of biosimilars and increased R&D investment are influencing the market trajectory.
Price Analysis
Historical Pricing Data
| Year |
Wholesale Acquisition Cost (WAC) |
Average Selling Price (ASP) |
Medicaid Rebate Price |
| 2020 |
$[Value] |
$[Value] |
$[Value] |
| 2021 |
$[Value] |
$[Value] |
$[Value] |
| 2022 |
$[Value] |
$[Value] |
$[Value] |
Current Price
- The average wholesale price (AWP) for the 30-count package is approximately $[Value].
- The average selling price (ASP) in hospitals and clinics is around $[Value].
- Medicaid rebates reduce actual net prices by an average of [X]%.
Price Projections (2023–2027)
| Year |
Expected WAC |
Expected ASP |
Notes |
| 2023 |
$[Value] |
$[Value] |
Continued generic uptake |
| 2024 |
$[Value] |
$[Value] |
Entry of new competitors; pricing pressure |
| 2025 |
$[Value] |
$[Value] |
Generic market maturation |
| 2026 |
$[Value] |
$[Value] |
Potential drug formulary adjustments |
| 2027 |
$[Value] |
$[Value] |
Expected stabilization or decline |
Price Drivers
- Market competition reduces prices.
- Patent cliffs and exclusivity loss accelerate generic penetration.
- Regulatory environment affects pricing policies.
- Supply chain factors impact distribution costs.
- Demand shifts driven by disease prevalence and treatment guidelines.
Regulatory and Policy Influence
- The FDA approval date for the generic influences market entry and pricing.
- Medicaid and Medicare reimbursement policies determine Actual Selling Prices.
- State-level formulary preferences and restrictions impact prescribing behaviors, shaping the price landscape.
Key Market Risks
- Accelerated generic uptake could suppress prices.
- Changes in reimbursement policies could lower profitability.
- Patent litigation or settlements may delay generic entry.
- New drug approvals in the same class could threaten market share.
Market Opportunities
- Expanding into international markets, especially Canada and Europe.
- Developing combination formulations to differentiate or extend patent life.
- Strategic alliances with pharmacy benefit managers (PBMs).
Conclusion
NDC 60505-0102 operates within a highly competitive, regulated environment with pricing influenced by patent status, market penetration, and reimbursement policies. Price projections reflect market maturity, with downward pressure expected from generic competition and regulatory changes.
Key Takeaways
- The market for NDC 60505-0102 remains competitive with significant price erosion anticipated over the next five years.
- Pricing is primarily driven by generic competition, with prices expected to stabilize from 2025 onward.
- Market growth is tempered by the increasing presence of biosimilars/biosimilar-like therapies and evolving prescribing trends.
- Reimbursement policies and regulatory developments are critical to pricing and market access.
- Opportunities exist in international markets, especially where generic penetration lags.
FAQs
Q1: What is the current market share of NDC 60505-0102?
It holds approximately X% of its therapeutic segment based on prescription volume data from 2022.
Q2: How does the price of this drug compare to the branded version?
The generic is priced at roughly [percentage]% below the brand, with a wholesale price around $[Value] per unit/package.
Q3: What factors could significantly impact future pricing?
Introduction of new competitors, regulatory shifts, changes in reimbursement policies, and patent litigation are primary factors.
Q4: Are there any regulatory hurdles that could affect the drug’s market?
Pending or future patent litigations, or delays in generic approval, could influence market entry timing and pricing.
Q5: Which international markets could offer growth opportunities?
Markets such as Canada, Europe, and parts of Asia offer potential due to lower generic penetration and different regulatory pathways.
References
-
U.S. Food and Drug Administration (FDA). (2022). Drug Approvals and Recalls. [online] Available at: https://www.fda.gov/drugs [Accessed date].
-
IQVIA. (2022). The IQVIA Pharmodel Database. [Data report].
-
Medicare.gov. (2022). Prescription Drug Pricing and Reimbursements. [online] Available at: https://www.medicare.gov.
-
MarketWatch Reports. (2022). US Generic Drug Market Trends. [online].
-
IQVIA Institute. (2021). The Global Use of Medicines in 2021. [Report].
Note: Specific data points such as prices, market shares, and growth percentages require access to proprietary databases or recent market reports. The provided analysis reflects typical market data patterns and projections based on historical trends.
